Maximising the potential of each and every asset we develop is a critical need for the pharma industry, recognising the value of efficient and effective investment in the right programs at the right time. However, to fully realise the true lifecycle value for an asset, teams need to consider an appropriate balance of both short-term goals and long-term strategy across a set of key lifecycle decision points. In this infographic, we highlight the six strategic decision points and key associated workstreams to consider for planning to create robust strategic plans for future success.
Early Lifecycle Management
Strategy Decision Point 1 – Launch Indication Prioritisation
Associated Workstreams
- MoA to indication mapping
- Broad indication assessment
- Prioritisation and initial LCM mapping
Strategy Decision Point 2 – Early Indication Optimisation
Associated Workstreams
- Launch indication gap analysis
- Integrated evidence strategy build
- Adjacency mapping and prioritisation
Strategy Decision Point 3 – Full Profile Optimisation
Associated Workstreams
- Core indication optimisation
- Full indication range prioritisation
- Solution strategy optimisation
Late Lifecycle Management
Strategy Decision Point 4 – Long-range LLC Preparation
Associated Workstreams
- Initial LLC situation analysis creation
- Product / solution optimisation for LLC
- Asset optimisation planning
Strategy Decision Point 5 – Commercial LLC Preparation
Associated Workstreams
- Commercial LLC tactic development
- Market archetyping and mapping
- Local LLC plan build & execution
Strategy Decision Point 6 – Established Brand Optimisation
Associated Workstreams
- Mapping of post-LoE opportunities
- Growth market strategy support
- EB portfolio management
